S. Brienza

4.2k total citations
58 papers, 3.2k citations indexed

About

S. Brienza is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, S. Brienza has authored 58 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 9 papers in Pathology and Forensic Medicine. Recurrent topics in S. Brienza's work include Cancer Treatment and Pharmacology (46 papers), Colorectal Cancer Treatments and Studies (30 papers) and Hepatocellular Carcinoma Treatment and Prognosis (6 papers). S. Brienza is often cited by papers focused on Cancer Treatment and Pharmacology (46 papers), Colorectal Cancer Treatments and Studies (30 papers) and Hepatocellular Carcinoma Treatment and Prognosis (6 papers). S. Brienza collaborates with scholars based in France, Switzerland and Italy. S. Brienza's co-authors include M. Itzhaki, Érick Gamelin, F Kunstlinger, Françis Lévi, G. Lockwood, M. Bayssas, Martin A. Graham, Jean-Louis Misset, Dennis Greenslade and C Jasmin and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

S. Brienza

57 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Brienza France	23	2.5k	699	682	484	473	58	3.2k
Rachid Zidani France	9	2.1k 0.8×	590 0.8×	826 1.2×	534 1.1×	341 0.7×	11	2.8k
Jean-Louis Misset France	22	1.6k 0.6×	513 0.7×	295 0.4×	314 0.6×	283 0.6×	42	2.5k
J.L. Misset France	16	1.6k 0.6×	482 0.7×	381 0.6×	348 0.7×	337 0.7×	41	2.6k
B Perpoint France	11	1.4k 0.5×	397 0.6×	439 0.6×	389 0.8×	275 0.6×	24	2.0k
Karl‐Heinz Thierauch Germany	19	908 0.4×	502 0.7×	369 0.5×	265 0.5×	279 0.6×	33	2.5k
David Chu United States	27	1.1k 0.4×	674 1.0×	138 0.2×	319 0.7×	171 0.4×	56	2.8k
Yuji Takebayashi Japan	35	1.8k 0.7×	502 0.7×	123 0.2×	404 0.8×	261 0.6×	82	3.6k
M. Boisdron‐Celle France	27	2.1k 0.8×	589 0.8×	133 0.2×	219 0.5×	267 0.6×	65	3.1k
B Hecquet France	22	887 0.3×	262 0.4×	49 0.1×	144 0.3×	266 0.6×	80	2.2k
R. Kaiser Germany	27	1.5k 0.6×	1.7k 2.4×	216 0.3×	338 0.7×	282 0.6×	115	3.4k

Countries citing papers authored by S. Brienza

Since Specialization

Citations

This map shows the geographic impact of S. Brienza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Brienza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Brienza more than expected).

Fields of papers citing papers by S. Brienza

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Brienza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Brienza. The network helps show where S. Brienza may publish in the future.

Co-authorship network of co-authors of S. Brienza

This figure shows the co-authorship network connecting the top 25 collaborators of S. Brienza. A scholar is included among the top collaborators of S. Brienza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Brienza. S. Brienza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tourneau, Christophe Le, Yungan Tao, Jean‐Pierre Delord, et al.. (2014). A phase I/II randomized study of Debio1143 combined with concurrent chemoradiation therapy (CCRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).. Journal of Clinical Oncology. 32(15_suppl). TPS6097–TPS6097. 1 indexed citations

Sugihara, Kenichi, Atsushi Ohtsu, Yasuhiro Shimada, et al.. (2011). Safety Analysis of FOLFOX4 Treatment in Colorectal Cancer Patients: A Comparison Between Two Asian Studies and Four Western Studies. Clinical Colorectal Cancer. 11(2). 127–137. 20 indexed citations

Sugihara, K., Atsushi Ohtsu, Yuko Shimada, et al.. (2010). Safety analysis of FOLFOX4 treatment in advanced/recurrent or adjuvant colorectal cancer in Asian and Western patients.. Journal of Clinical Oncology. 28(15_suppl). 3611–3611. 1 indexed citations

Delozier, T., Jean‐Paul Guastalla, Alejandro Yovine, et al.. (2006). A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Anti-Cancer Drugs. 17(9). 1067–1073. 12 indexed citations

Delaloge, Suzette, M. Tubiana-Hulin, Andrew Wardley, et al.. (2004). A multistep randomized phase II/III trial comparing oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN)+FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results. Journal of Clinical Oncology. 22(14_suppl). 660–660. 6 indexed citations

Boisdron‐Celle, M., et al.. (2002). Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. Cancer Chemotherapy and Pharmacology. 49(3). 235–243. 18 indexed citations

Garufi, Carlo, S. Brienza, M.A. Bensmaïne, et al.. (2000). Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. Anti-Cancer Drugs. 11(6). 495–501. 21 indexed citations

Germann, N., S. Brienza, Jean‐François Emile, et al.. (1999). Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Annals of Oncology. 10(3). 351–354. 44 indexed citations

Brienza, S., M.A. Bensmaïne, P Soulié, et al.. (1999). Oxaliplatin added to 5-fluorouracil-based therapy (5-FU ± FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program. Annals of Oncology. 10(11). 1311–1316. 45 indexed citations

10.

Zidani, Rachid, S. Brienza, Luigi Dogliotti, et al.. (1999). A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. Cancer. 85(12). 2532–2540. 107 indexed citations

11.

Gamelin, Érick, M. Boisdron‐Celle, Alain Turcant, et al.. (1998). Determination of unbound platinum after oxaliplatin administration. Anti-Cancer Drugs. 9(3). 223–228. 12 indexed citations

12.

Delva, R., E. Gamelin, P. Maillart, et al.. (1997). Oxaliplatin (LOHP) and 5-fluorouracil (5-FU) synergism in advanced colorectal cancer patients (ACRC). European Journal of Cancer. 33. S167–S167. 5 indexed citations

13.

Chollet, P., M.A. Bensmaïne, S. Brienza, et al.. (1996). Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Annals of Oncology. 7(10). 1065–1070. 124 indexed citations

14.

Bertheault-Cvitkovic, F., S. Brienza, R. Adam, et al.. (1996). Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.. Journal of Clinical Oncology. 14(11). 2950–2958. 125 indexed citations

15.

Lévi, Françis, S. Brienza, Petra Deprés-Brummer, et al.. (1993). Implications of Chronobiology for 5-Fluorouracil (5-Fu) Efficacy. Advances in experimental medicine and biology. 339. 169–186. 2 indexed citations

16.

Bertheault-Cvitkovic, F., Françis Lévi, S. Brienza, et al.. (1993). Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. European Journal of Cancer. 29(13). 1851–1854. 25 indexed citations

17.

Brienza, S., J Gastiaburu, Abderrahim Fandi, et al.. (1993). Neurotoxicite (NTX) of long term oxaliplatin (L-ORP) therapy. European Journal of Cancer. 29. S117–S117. 2 indexed citations

18.

Lévi, Francis, B Perpoint, Carlo Garufi, et al.. (1993). Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. European Journal of Cancer. 29(9). 1280–1284. 162 indexed citations

19.

Mathé, G, et al.. (1992). Retrospective study correlating clinical infectious history and peripheral blood T-cell subpopulations in cancer, GvH and HIV+ patients. Biomedicine & Pharmacotherapy. 46(1). 17–19. 2 indexed citations

20.

Caussanel, J. P., Francis Lévi, S. Brienza, et al.. (1990). Phase I Trial of 5-Day Continuous Venous Infusion of Oxaliplatin at Circadian Rhythm-Modulated Rate Compared With Constant Rate. JNCI Journal of the National Cancer Institute. 82(12). 1046–1050. 210 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact